nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Loss of libido—Methotrexate—muscle cancer	0.0161	0.0161	CcSEcCtD
Doxylamine—Polyuria—Vincristine—muscle cancer	0.0127	0.0127	CcSEcCtD
Doxylamine—Body temperature decreased—Doxorubicin—muscle cancer	0.0115	0.0115	CcSEcCtD
Doxylamine—Hypothermia—Doxorubicin—muscle cancer	0.0115	0.0115	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.0112	0.0112	CcSEcCtD
Doxylamine—Lacrimation—Doxorubicin—muscle cancer	0.011	0.011	CcSEcCtD
Doxylamine—Liver disorder—Methotrexate—muscle cancer	0.0109	0.0109	CcSEcCtD
Doxylamine—Urinary retention—Vincristine—muscle cancer	0.0106	0.0106	CcSEcCtD
Doxylamine—Dehydration—Vincristine—muscle cancer	0.0104	0.0104	CcSEcCtD
Doxylamine—Pancytopenia—Dactinomycin—muscle cancer	0.0102	0.0102	CcSEcCtD
Doxylamine—Redness—Doxorubicin—muscle cancer	0.00956	0.00956	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00954	0.00954	CcSEcCtD
Doxylamine—Pancytopenia—Vincristine—muscle cancer	0.00916	0.00916	CcSEcCtD
Doxylamine—Agranulocytosis—Dactinomycin—muscle cancer	0.00898	0.00898	CcSEcCtD
Doxylamine—Hepatitis—Dactinomycin—muscle cancer	0.00864	0.00864	CcSEcCtD
Doxylamine—Depression—Vincristine—muscle cancer	0.00857	0.00857	CcSEcCtD
Doxylamine—Bone disorder—Methotrexate—muscle cancer	0.00825	0.00825	CcSEcCtD
Doxylamine—Sweating—Vincristine—muscle cancer	0.00824	0.00824	CcSEcCtD
Doxylamine—Erythema multiforme—Dactinomycin—muscle cancer	0.00817	0.00817	CcSEcCtD
Doxylamine—Cramp muscle—Etoposide—muscle cancer	0.00814	0.00814	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00814	0.00814	CcSEcCtD
Doxylamine—Flushing—Dactinomycin—muscle cancer	0.00802	0.00802	CcSEcCtD
Doxylamine—Bronchospasm—Etoposide—muscle cancer	0.00768	0.00768	CcSEcCtD
Doxylamine—Hallucination—Vincristine—muscle cancer	0.00768	0.00768	CcSEcCtD
Doxylamine—Urinary tract disorder—Vincristine—muscle cancer	0.00762	0.00762	CcSEcCtD
Doxylamine—Sweating increased—Etoposide—muscle cancer	0.00761	0.00761	CcSEcCtD
Doxylamine—Urethral disorder—Vincristine—muscle cancer	0.00756	0.00756	CcSEcCtD
Doxylamine—Erythema—Dactinomycin—muscle cancer	0.00752	0.00752	CcSEcCtD
Doxylamine—Pancytopenia—Etoposide—muscle cancer	0.00742	0.00742	CcSEcCtD
Doxylamine—Cardiac disorder—Vincristine—muscle cancer	0.00716	0.00716	CcSEcCtD
Doxylamine—Bone disorder—Doxorubicin—muscle cancer	0.00715	0.00715	CcSEcCtD
Doxylamine—Lacrimation increased—Doxorubicin—muscle cancer	0.00701	0.00701	CcSEcCtD
Doxylamine—Ill-defined disorder—Dactinomycin—muscle cancer	0.00698	0.00698	CcSEcCtD
Doxylamine—Mediastinal disorder—Vincristine—muscle cancer	0.00695	0.00695	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.0069	0.0069	CcSEcCtD
Doxylamine—Malaise—Dactinomycin—muscle cancer	0.00678	0.00678	CcSEcCtD
Doxylamine—Leukopenia—Dactinomycin—muscle cancer	0.00673	0.00673	CcSEcCtD
Doxylamine—Agranulocytosis—Etoposide—muscle cancer	0.0065	0.0065	CcSEcCtD
Doxylamine—Discomfort—Dactinomycin—muscle cancer	0.00632	0.00632	CcSEcCtD
Doxylamine—Urinary tract disorder—Etoposide—muscle cancer	0.00617	0.00617	CcSEcCtD
Doxylamine—Agitation—Vincristine—muscle cancer	0.00617	0.00617	CcSEcCtD
Doxylamine—Polyuria—Methotrexate—muscle cancer	0.00616	0.00616	CcSEcCtD
Doxylamine—Urethral disorder—Etoposide—muscle cancer	0.00613	0.00613	CcSEcCtD
Doxylamine—Vertigo—Vincristine—muscle cancer	0.00603	0.00603	CcSEcCtD
Doxylamine—Leukopenia—Vincristine—muscle cancer	0.00601	0.00601	CcSEcCtD
Doxylamine—Thrombocytopenia—Dactinomycin—muscle cancer	0.00601	0.00601	CcSEcCtD
Doxylamine—Erythema multiforme—Etoposide—muscle cancer	0.00591	0.00591	CcSEcCtD
Doxylamine—Anorexia—Dactinomycin—muscle cancer	0.00585	0.00585	CcSEcCtD
Doxylamine—Eye disorder—Etoposide—muscle cancer	0.00584	0.00584	CcSEcCtD
Doxylamine—Convulsion—Vincristine—muscle cancer	0.00582	0.00582	CcSEcCtD
Doxylamine—Flushing—Etoposide—muscle cancer	0.0058	0.0058	CcSEcCtD
Doxylamine—Cardiac disorder—Etoposide—muscle cancer	0.0058	0.0058	CcSEcCtD
Doxylamine—Immune system disorder—Etoposide—muscle cancer	0.00565	0.00565	CcSEcCtD
Doxylamine—Mediastinal disorder—Etoposide—muscle cancer	0.00563	0.00563	CcSEcCtD
Doxylamine—Anaphylactic shock—Vincristine—muscle cancer	0.00548	0.00548	CcSEcCtD
Doxylamine—Nervous system disorder—Vincristine—muscle cancer	0.00538	0.00538	CcSEcCtD
Doxylamine—Thrombocytopenia—Vincristine—muscle cancer	0.00537	0.00537	CcSEcCtD
Doxylamine—Decreased appetite—Dactinomycin—muscle cancer	0.00533	0.00533	CcSEcCtD
Doxylamine—Hyperhidrosis—Vincristine—muscle cancer	0.0053	0.0053	CcSEcCtD
Doxylamine—Fatigue—Dactinomycin—muscle cancer	0.00529	0.00529	CcSEcCtD
Doxylamine—Muscle spasms—Etoposide—muscle cancer	0.00523	0.00523	CcSEcCtD
Doxylamine—Anorexia—Vincristine—muscle cancer	0.00523	0.00523	CcSEcCtD
Doxylamine—Irritability—Methotrexate—muscle cancer	0.00517	0.00517	CcSEcCtD
Doxylamine—Mood swings—Methotrexate—muscle cancer	0.00513	0.00513	CcSEcCtD
Doxylamine—Hypotension—Vincristine—muscle cancer	0.00512	0.00512	CcSEcCtD
Doxylamine—Feeling abnormal—Dactinomycin—muscle cancer	0.00506	0.00506	CcSEcCtD
Doxylamine—Ill-defined disorder—Etoposide—muscle cancer	0.00505	0.00505	CcSEcCtD
Doxylamine—Insomnia—Vincristine—muscle cancer	0.00496	0.00496	CcSEcCtD
Doxylamine—Malaise—Etoposide—muscle cancer	0.00491	0.00491	CcSEcCtD
Doxylamine—Breast disorder—Methotrexate—muscle cancer	0.00489	0.00489	CcSEcCtD
Doxylamine—Vertigo—Etoposide—muscle cancer	0.00489	0.00489	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00487	0.00487	CcSEcCtD
Doxylamine—Leukopenia—Etoposide—muscle cancer	0.00487	0.00487	CcSEcCtD
Doxylamine—Decreased appetite—Vincristine—muscle cancer	0.00477	0.00477	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00473	0.00473	CcSEcCtD
Doxylamine—Fatigue—Vincristine—muscle cancer	0.00473	0.00473	CcSEcCtD
Doxylamine—Convulsion—Etoposide—muscle cancer	0.00471	0.00471	CcSEcCtD
Doxylamine—Constipation—Vincristine—muscle cancer	0.00469	0.00469	CcSEcCtD
Doxylamine—Diplopia—Doxorubicin—muscle cancer	0.00469	0.00469	CcSEcCtD
Doxylamine—Affect lability—Doxorubicin—muscle cancer	0.00461	0.00461	CcSEcCtD
Doxylamine—Pancreatitis—Methotrexate—muscle cancer	0.00459	0.00459	CcSEcCtD
Doxylamine—Discomfort—Etoposide—muscle cancer	0.00458	0.00458	CcSEcCtD
Doxylamine—Hypersensitivity—Dactinomycin—muscle cancer	0.00452	0.00452	CcSEcCtD
Doxylamine—Abdominal discomfort—Methotrexate—muscle cancer	0.00448	0.00448	CcSEcCtD
Doxylamine—Confusional state—Etoposide—muscle cancer	0.00448	0.00448	CcSEcCtD
Doxylamine—Pancytopenia—Methotrexate—muscle cancer	0.00444	0.00444	CcSEcCtD
Doxylamine—Anaphylactic shock—Etoposide—muscle cancer	0.00444	0.00444	CcSEcCtD
Doxylamine—Mood swings—Doxorubicin—muscle cancer	0.00444	0.00444	CcSEcCtD
Doxylamine—Asthenia—Dactinomycin—muscle cancer	0.0044	0.0044	CcSEcCtD
Doxylamine—Dehydration—Doxorubicin—muscle cancer	0.00436	0.00436	CcSEcCtD
Doxylamine—Thrombocytopenia—Etoposide—muscle cancer	0.00435	0.00435	CcSEcCtD
Doxylamine—Tachycardia—Etoposide—muscle cancer	0.00433	0.00433	CcSEcCtD
Doxylamine—Hyperhidrosis—Etoposide—muscle cancer	0.00429	0.00429	CcSEcCtD
Doxylamine—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00428	0.00428	CcSEcCtD
Doxylamine—Breast disorder—Doxorubicin—muscle cancer	0.00423	0.00423	CcSEcCtD
Doxylamine—Anorexia—Etoposide—muscle cancer	0.00423	0.00423	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.00422	0.00422	CcSEcCtD
Doxylamine—Diarrhoea—Dactinomycin—muscle cancer	0.0042	0.0042	CcSEcCtD
Doxylamine—Nasopharyngitis—Doxorubicin—muscle cancer	0.00419	0.00419	CcSEcCtD
Doxylamine—Drowsiness—Methotrexate—muscle cancer	0.00417	0.00417	CcSEcCtD
Doxylamine—Depression—Methotrexate—muscle cancer	0.00416	0.00416	CcSEcCtD
Doxylamine—Hypotension—Etoposide—muscle cancer	0.00415	0.00415	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.00413	0.00413	CcSEcCtD
Doxylamine—Hypersensitivity—Vincristine—muscle cancer	0.00404	0.00404	CcSEcCtD
Doxylamine—Sweating—Methotrexate—muscle cancer	0.004	0.004	CcSEcCtD
Doxylamine—Pancreatitis—Doxorubicin—muscle cancer	0.00397	0.00397	CcSEcCtD
Doxylamine—Dyspnoea—Etoposide—muscle cancer	0.00396	0.00396	CcSEcCtD
Doxylamine—Somnolence—Etoposide—muscle cancer	0.00395	0.00395	CcSEcCtD
Doxylamine—Asthenia—Vincristine—muscle cancer	0.00393	0.00393	CcSEcCtD
Doxylamine—Vomiting—Dactinomycin—muscle cancer	0.0039	0.0039	CcSEcCtD
Doxylamine—Agranulocytosis—Methotrexate—muscle cancer	0.00389	0.00389	CcSEcCtD
Doxylamine—Rash—Dactinomycin—muscle cancer	0.00387	0.00387	CcSEcCtD
Doxylamine—Decreased appetite—Etoposide—muscle cancer	0.00386	0.00386	CcSEcCtD
Doxylamine—Pancytopenia—Doxorubicin—muscle cancer	0.00385	0.00385	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00383	0.00383	CcSEcCtD
Doxylamine—Fatigue—Etoposide—muscle cancer	0.00383	0.00383	CcSEcCtD
Doxylamine—Constipation—Etoposide—muscle cancer	0.0038	0.0038	CcSEcCtD
Doxylamine—Diarrhoea—Vincristine—muscle cancer	0.00375	0.00375	CcSEcCtD
Doxylamine—Hepatitis—Methotrexate—muscle cancer	0.00374	0.00374	CcSEcCtD
Doxylamine—Urinary tract disorder—Methotrexate—muscle cancer	0.0037	0.0037	CcSEcCtD
Doxylamine—Urethral disorder—Methotrexate—muscle cancer	0.00367	0.00367	CcSEcCtD
Doxylamine—Feeling abnormal—Etoposide—muscle cancer	0.00366	0.00366	CcSEcCtD
Doxylamine—Nausea—Dactinomycin—muscle cancer	0.00364	0.00364	CcSEcCtD
Doxylamine—Dizziness—Vincristine—muscle cancer	0.00363	0.00363	CcSEcCtD
Doxylamine—Drowsiness—Doxorubicin—muscle cancer	0.00361	0.00361	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.00358	0.00358	CcSEcCtD
Doxylamine—Erythema multiforme—Methotrexate—muscle cancer	0.00354	0.00354	CcSEcCtD
Doxylamine—Urticaria—Etoposide—muscle cancer	0.00353	0.00353	CcSEcCtD
Doxylamine—Eye disorder—Methotrexate—muscle cancer	0.0035	0.0035	CcSEcCtD
Doxylamine—Vomiting—Vincristine—muscle cancer	0.00349	0.00349	CcSEcCtD
Doxylamine—Cardiac disorder—Methotrexate—muscle cancer	0.00347	0.00347	CcSEcCtD
Doxylamine—Sweating—Doxorubicin—muscle cancer	0.00346	0.00346	CcSEcCtD
Doxylamine—Rash—Vincristine—muscle cancer	0.00346	0.00346	CcSEcCtD
Doxylamine—Dermatitis—Vincristine—muscle cancer	0.00345	0.00345	CcSEcCtD
Doxylamine—Immune system disorder—Methotrexate—muscle cancer	0.00338	0.00338	CcSEcCtD
Doxylamine—Mediastinal disorder—Methotrexate—muscle cancer	0.00337	0.00337	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—muscle cancer	0.00337	0.00337	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—muscle cancer	0.0033	0.0033	CcSEcCtD
Doxylamine—Hypersensitivity—Etoposide—muscle cancer	0.00327	0.00327	CcSEcCtD
Doxylamine—Erythema—Methotrexate—muscle cancer	0.00326	0.00326	CcSEcCtD
Doxylamine—Nausea—Vincristine—muscle cancer	0.00326	0.00326	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—muscle cancer	0.00324	0.00324	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—muscle cancer	0.0032	0.0032	CcSEcCtD
Doxylamine—Asthenia—Etoposide—muscle cancer	0.00319	0.00319	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—muscle cancer	0.00318	0.00318	CcSEcCtD
Doxylamine—Pruritus—Etoposide—muscle cancer	0.00314	0.00314	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—muscle cancer	0.00307	0.00307	CcSEcCtD
Doxylamine—Diarrhoea—Etoposide—muscle cancer	0.00304	0.00304	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—muscle cancer	0.00303	0.00303	CcSEcCtD
Doxylamine—Ill-defined disorder—Methotrexate—muscle cancer	0.00302	0.00302	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—muscle cancer	0.00301	0.00301	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—muscle cancer	0.00301	0.00301	CcSEcCtD
Doxylamine—Malaise—Methotrexate—muscle cancer	0.00294	0.00294	CcSEcCtD
Doxylamine—Dizziness—Etoposide—muscle cancer	0.00294	0.00294	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—muscle cancer	0.00293	0.00293	CcSEcCtD
Doxylamine—Vertigo—Methotrexate—muscle cancer	0.00293	0.00293	CcSEcCtD
Doxylamine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00292	0.00292	CcSEcCtD
Doxylamine—Leukopenia—Methotrexate—muscle cancer	0.00292	0.00292	CcSEcCtD
Doxylamine—Convulsion—Methotrexate—muscle cancer	0.00282	0.00282	CcSEcCtD
Doxylamine—Vomiting—Etoposide—muscle cancer	0.00282	0.00282	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—muscle cancer	0.00282	0.00282	CcSEcCtD
Doxylamine—Rash—Etoposide—muscle cancer	0.0028	0.0028	CcSEcCtD
Doxylamine—Dermatitis—Etoposide—muscle cancer	0.0028	0.0028	CcSEcCtD
Doxylamine—Discomfort—Methotrexate—muscle cancer	0.00274	0.00274	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—muscle cancer	0.00271	0.00271	CcSEcCtD
Doxylamine—Confusional state—Methotrexate—muscle cancer	0.00268	0.00268	CcSEcCtD
Doxylamine—Anaphylactic shock—Methotrexate—muscle cancer	0.00266	0.00266	CcSEcCtD
Doxylamine—Nausea—Etoposide—muscle cancer	0.00264	0.00264	CcSEcCtD
Doxylamine—Ill-defined disorder—Doxorubicin—muscle cancer	0.00262	0.00262	CcSEcCtD
Doxylamine—Nervous system disorder—Methotrexate—muscle cancer	0.00261	0.00261	CcSEcCtD
Doxylamine—Thrombocytopenia—Methotrexate—muscle cancer	0.0026	0.0026	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—muscle cancer	0.00259	0.00259	CcSEcCtD
Doxylamine—Hyperhidrosis—Methotrexate—muscle cancer	0.00257	0.00257	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—muscle cancer	0.00255	0.00255	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—muscle cancer	0.00254	0.00254	CcSEcCtD
Doxylamine—Anorexia—Methotrexate—muscle cancer	0.00254	0.00254	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—muscle cancer	0.00253	0.00253	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—muscle cancer	0.00249	0.00249	CcSEcCtD
Doxylamine—Hypotension—Methotrexate—muscle cancer	0.00249	0.00249	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—muscle cancer	0.00245	0.00245	CcSEcCtD
Doxylamine—Insomnia—Methotrexate—muscle cancer	0.00241	0.00241	CcSEcCtD
Doxylamine—Anxiety—Doxorubicin—muscle cancer	0.00239	0.00239	CcSEcCtD
Doxylamine—Discomfort—Doxorubicin—muscle cancer	0.00237	0.00237	CcSEcCtD
Doxylamine—Dyspnoea—Methotrexate—muscle cancer	0.00237	0.00237	CcSEcCtD
Doxylamine—Somnolence—Methotrexate—muscle cancer	0.00236	0.00236	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—muscle cancer	0.00235	0.00235	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—muscle cancer	0.00232	0.00232	CcSEcCtD
Doxylamine—Decreased appetite—Methotrexate—muscle cancer	0.00231	0.00231	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—muscle cancer	0.0023	0.0023	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.0023	0.0023	CcSEcCtD
Doxylamine—Fatigue—Methotrexate—muscle cancer	0.00229	0.00229	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—muscle cancer	0.00226	0.00226	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—muscle cancer	0.00226	0.00226	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—muscle cancer	0.00225	0.00225	CcSEcCtD
Doxylamine—Hyperhidrosis—Doxorubicin—muscle cancer	0.00223	0.00223	CcSEcCtD
Doxylamine—Anorexia—Doxorubicin—muscle cancer	0.0022	0.0022	CcSEcCtD
Doxylamine—Feeling abnormal—Methotrexate—muscle cancer	0.00219	0.00219	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—muscle cancer	0.00215	0.00215	CcSEcCtD
Doxylamine—Urticaria—Methotrexate—muscle cancer	0.00211	0.00211	CcSEcCtD
Doxylamine—Insomnia—Doxorubicin—muscle cancer	0.00208	0.00208	CcSEcCtD
Doxylamine—Dyspnoea—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—muscle cancer	0.00205	0.00205	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—muscle cancer	0.002	0.002	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—muscle cancer	0.00199	0.00199	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—muscle cancer	0.00197	0.00197	CcSEcCtD
Doxylamine—Hypersensitivity—Methotrexate—muscle cancer	0.00196	0.00196	CcSEcCtD
Doxylamine—Asthenia—Methotrexate—muscle cancer	0.00191	0.00191	CcSEcCtD
Doxylamine—Feeling abnormal—Doxorubicin—muscle cancer	0.0019	0.0019	CcSEcCtD
Doxylamine—Pruritus—Methotrexate—muscle cancer	0.00188	0.00188	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—muscle cancer	0.00183	0.00183	CcSEcCtD
Doxylamine—Diarrhoea—Methotrexate—muscle cancer	0.00182	0.00182	CcSEcCtD
Doxylamine—Dizziness—Methotrexate—muscle cancer	0.00176	0.00176	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—muscle cancer	0.0017	0.0017	CcSEcCtD
Doxylamine—Vomiting—Methotrexate—muscle cancer	0.00169	0.00169	CcSEcCtD
Doxylamine—Rash—Methotrexate—muscle cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Dermatitis—Methotrexate—muscle cancer	0.00168	0.00168	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—muscle cancer	0.00165	0.00165	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—muscle cancer	0.00163	0.00163	CcSEcCtD
Doxylamine—Nausea—Methotrexate—muscle cancer	0.00158	0.00158	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—muscle cancer	0.00158	0.00158	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—muscle cancer	0.00152	0.00152	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—muscle cancer	0.00146	0.00146	CcSEcCtD
Doxylamine—Rash—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—muscle cancer	0.00145	0.00145	CcSEcCtD
Doxylamine—Nausea—Doxorubicin—muscle cancer	0.00137	0.00137	CcSEcCtD
